Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GLAGOV Imaging Study Of Amgen's Repatha Bodes Well For PCSK9 Class

Executive Summary

Positive results in GLAGOV lift PCSK9 inhibitor Repatha, but most likely are still not enough to get rid of reimbursement restrictions for the class, analysts say.

You may also be interested in...



Amgen's Repatha Emerges Unscathed In GLAGOV PCSK9 Imaging Study

Full data from GLAGOV imaging study shows value of driving LDL below 60 mg/dL and presents no red flags for outcomes data due in first quarter of 2017.

PCSK9 Inhibitors' First Birthday Brings Sluggish Sales And More Bad Press

Analysis published in the Journal of the American Medical Association is the latest to argue that PCSK9 inhibitors are not cost-effective.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.

Topics

Related Companies

UsernamePublicRestriction

Register

SC097339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel